Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12386566 | 1.00 | GABRR1 (0.50) | GABRR1CYP1A2BLMPMP22ACE2 | |
| SCHEMBL14608893 | 0.82 | PMP22 (0.64) | GABRR1CYP1A2BLMPMP22ACE2 | |
| SCHEMBL15601866 | 0.82 | PMP22 (0.64) | GABRR1CYP1A2BLMPMP22ACE2 | |
| SCHEMBL15339726 | 0.81 | NLRP3 (0.36) | GABRR1CYP1A2PMP22 | |
| SCHEMBL18215174 | 0.81 | GABRR1 (0.50) | GABRR1CYP1A2BLMPMP22ACE2 | |
| SCHEMBL7805773 | 0.81 | NLRP3 (0.36) | GABRR1CYP1A2PMP22 | |
| SCHEMBL14611452 | 0.79 | GABRR1 (0.54) | GABRR1CYP1A2BLMPMP22ACE2 | |
| SCHEMBL27810909 | 0.79 | GABRR1 (0.48) | GABRR1CYP1A2BLMPMP22ACE2 | |
| SCHEMBL5139179 | 0.79 | GABRR1 (0.72) | GABRR1CYP1A2BLMACE2LTA4H | |
| Methionine Sulfone SCHEMBL1527360 | 0.76 | PMP22 (0.69) | CYP1A2BLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256912-A1 | Stabilized Variant MAML Peptides and Uses Thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256912-A1 | Stabilized Variant MAML Peptides and Uses Thereof | NOTCH1, MDN1, NOTCH2 | GABRR1 3995/4885CYP1A2 4808/4885BLM 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.